GlassScriptPhysician profile
Robert W Isfort
NPI 1639494032
$161,572.42
in general payments reported to CMS, 2019-2025
46 companies · $48K in 2025
The $48K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,151 · 2021: $19K · 2022: $27K · 2023: $28K · 2024: $26K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Consulting Fee: $28K · Food and Beverage: $11K · Travel and Lodging: $4,593 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,982.86 |
| Consulting Fee | $28,139.50 |
| Food and Beverage | $10,722.34 |
| Travel and Lodging | $4,592.71 |
| Education | $234.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $50,798.03 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $31,592.67 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Janssen Biotech, INC. | $24,749.57 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $18,182.40 | 2023-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $10,173.32 | 2019-2025 | Tremfya, Stelara |
| Eli Lilly and Company | $8,575.80 | 2024-2025 | Omvoh |
| Abbvie INC. | $7,412.47 | 2019-2025 | |
| Celgene Corporation | $4,320.19 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $932.88 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Genentech, INC. | $878.55 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $594.35 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $418.47 | 2021-2025 | |
| Madrigal Pharmaceuticals | $359.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $336.24 | 2020-2025 | Linzess |
| Pfizer INC. | $326.71 | 2019-2025 |
Show all 44 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Isfort listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.